Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Account Payables (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Change in Account Payables for 9 consecutive years, with $575000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 86.05% to $575000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Dec 2025, down 449.58% year-over-year, with the annual reading at -$2.5 million for FY2025, 449.58% down from the prior year.
  • Change in Account Payables hit $575000.0 in Q4 2025 for Sutro Biopharma, down from $2.7 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.1 million in Q4 2024 to a low of -$3.8 million in Q2 2025.
  • Historically, Change in Account Payables has averaged $226650.0 across 5 years, with a median of -$292500.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: tumbled 1058.08% in 2024 and later surged 2281.3% in 2025.
  • Year by year, Change in Account Payables stood at -$1.8 million in 2021, then surged by 47.24% to -$937000.0 in 2022, then surged by 532.98% to $4.1 million in 2023, then increased by 1.58% to $4.1 million in 2024, then crashed by 86.05% to $575000.0 in 2025.
  • Business Quant data shows Change in Account Payables for STRO at $575000.0 in Q4 2025, $2.7 million in Q3 2025, and -$3.8 million in Q2 2025.